Consequences of the judicialization of health policies: The cost of medicines for mucopolysaccharidosis;Consequências da judicialização das políticas de saúde: Custos de medicamentos para as mucopolissacaridoses

Cadernos de Saude Publica

Volumn 28, Issue 3, 2012, Pages 479-489

  Diniz, Debora ^a,b   Medeiros, Marcelo ^b   Schwartz, Ida Vanessa D ^c,d  

^a Anis Instituto de Bioética Direitos Humanos e Gênero   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Health policy; Jurisprudence; Mucopolysaccharidoses

Indexed keywords

ESSENTIAL DRUG; IDURONATE 2 SULFATASE; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

BRAZIL; DRUG COST; ECONOMICS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; LEGAL ASPECT; MUCOPOLYSACCHARIDOSIS; ORGANIZATION AND MANAGEMENT; RARE DISEASE; REVIEW;

BRAZIL; DRUG COSTS; DRUGS, ESSENTIAL; HEALTH EXPENDITURES; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; IDURONATE SULFATASE; MUCOPOLYSACCHARIDOSES; N-ACETYLGALACTOSAMINE-4-SULFATASE; PUBLIC SECTOR; RARE DISEASES; RECOMBINANT PROTEINS;

EID: 84858385816     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/S0102-311X2012000300008     Document Type: Review

References (9)

1. Ventura M, Simas L, Pepe VLE, Schramm FR Judicialização da saúde, acesso à justiça e à efetividade do direito à saúde. Physis (Rio J.) 2010; 20:77-100.
2. Andrade E, Machado CD, Faleiros DR, Szuster DAC, Guerra Júnior AA, Silva GD, et al. A judicialização da saúde e a política nacional de assistência farmacêutica no Brasil: gestão da clínica e medicalização da justiça. Rev Méd Minas Gerais 2008; 18 (4 Suppl 4):S46-50.
3. Ultra orphan drugs for lysosomal storage disorders. 2009. http://www.specialisedservices.nhs.uk/library/22/A_Guideline_Comparison_and_Survey_of_International_Current_Practice_in_Ultra_Orphan_Drugs_for_Lysosomal_Storage_Disorders.pdf(acessado em 31/Ago/2011).
4. Boy R, Schwartz IV, Krug BC, Santana-da-Silva LC, Steiner CE, Acosta AX, et al. Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I. J Med Ethics 2011; 37:233-9.
5. Neufeld E, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. 7th Ed. New York: McGraw-Hill; 2001. p. 3421-52.
6. Vieira T, Schwartz I, Munoz V, Pinto L, Steiner C, Ribeiro M, et al. Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? Am J Med Genet 2008; 146A:1741-7.
7. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda CS, et al. Enzyme replacement therapy for mucopolysaccharidosis IV: a phase 3, randomized, double-blind, placebo controlled, multinational study of recombinant human n-acetilgalactosamine 4-sulfatase (recombinant human arylsulfatase B or RHASB) and follow-on open label extension study. J Pediatr 2006; 148:533-9.
8. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8:465-73.
9. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis i: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J Pediatr 2004; 104:581-8.